Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Gottfried E. Konecny, Neil J. Finkler, Agustin A. García, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 6, pp. 686-694
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1635
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant, et al.
International Journal of Gynecological Cancer (2015) Vol. 26, Iss. 1, pp. 2-30
Open Access | Times Cited: 695
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 686
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 5, pp. 437-448
Open Access | Times Cited: 324
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Molecular Genetics of Endometrial Carcinoma
Daphne W. Bell, Lora H. Ellenson
Annual Review of Pathology Mechanisms of Disease (2018) Vol. 14, Iss. 1, pp. 339-367
Closed Access | Times Cited: 241
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189
Treatment strategies for endometrial cancer: current practice and perspective
Yeh Chen Lee, Stéphanie Lheureux, Amit M. Oza
Current Opinion in Obstetrics & Gynecology (2016) Vol. 29, Iss. 1, pp. 47-58
Closed Access | Times Cited: 169
Endometrial cancer: Molecular markers and management of advanced stage disease
Rebecca C. Arend, Bayley Jones, Alba Martínez, et al.
Gynecologic Oncology (2018) Vol. 150, Iss. 3, pp. 569-580
Closed Access | Times Cited: 165
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young Kwang Chae, Fangxin Hong, Christos Vaklavas, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 21, pp. 2407-2417
Open Access | Times Cited: 146
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, et al.
Cell Proliferation (2021) Vol. 54, Iss. 4
Open Access | Times Cited: 133
Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
Mohammad Mashreghi, Hassan Azarpara, Mahere Rezazade Bazaz, et al.
Journal of Cellular Physiology (2017) Vol. 233, Iss. 4, pp. 2949-2965
Closed Access | Times Cited: 122
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 764-774
Open Access | Times Cited: 105
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Antonella De Luca, Riziero Esposito Abate, Anna Maria Rachiglio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6856-6856
Open Access | Times Cited: 99
New therapies for advanced, recurrent, and metastatic endometrial cancers
Vicky Makker, Angela K. Green, Robert M. Wenham, et al.
Gynecologic Oncology Research and Practice (2017) Vol. 4, Iss. 1
Open Access | Times Cited: 97
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 52
Advanced and recurrent endometrial cancer: State of the art and future perspectives
Francesca Tronconi, Camilla Nero, Elena Giudice, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 180, pp. 103851-103851
Closed Access | Times Cited: 42
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 32
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Jharna Datta, Senthilkumar Damodaran, Hannah Parks, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 4, pp. 614-624
Open Access | Times Cited: 85
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence Hall, Yi Yu, Sudharshan Eathiraj, et al.
PLoS ONE (2016) Vol. 11, Iss. 9, pp. e0162594-e0162594
Open Access | Times Cited: 84
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Sébastien Taurin, Chieh-Hsiang Yang, Maria Reyes, et al.
International Journal of Gynecological Cancer (2017) Vol. 28, Iss. 1, pp. 152-160
Open Access | Times Cited: 78
Second-line lenvatinib in patients with recurrent endometrial cancer
Ignace Vergote, Matthew A. Powell, Michael Teneriello, et al.
Gynecologic Oncology (2020) Vol. 156, Iss. 3, pp. 575-582
Open Access | Times Cited: 63
Current progress in cancer treatment by targeting FGFR signaling
Sicheng Du, Ying Zhang, Jianming Xu
Cancer Biology and Medicine (2023) Vol. 20, Iss. 7, pp. 490-499
Open Access | Times Cited: 23
Recent Advances in Endometrial Cancer
Arthur-Quan Tran, Paola A. Gehrig
F1000Research (2017) Vol. 6, pp. 81-81
Open Access | Times Cited: 53
Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
Wenya Zhou, Wenya Zhou, Hong Zheng, et al.
Cancer Biology and Medicine (2016) Vol. 13, Iss. 2, pp. 260-268
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top